Nothing said here yet.
to join the conversation.
| Alan Armstrong | Buy | $8.0K | Mon, Mar 30 | Tue, Jul 21 |
Genmab has seen a sharp rerating on the back of recent oncology trial successes, which puts a fresh spotlight on whether the current share price lines up with the cash flows its pipeline may ultimately produce.
Genmab is going to approach global agencies based on the interim Phase III data for its bispecific in first-line HNSCC.
The drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become a new treatment standard for a form of head and neck cancer.
Investors responded positively to stronger financial performance and progress in medical research.
Genmab A/S (NASDAQ:GMAB) said three positive Phase III readouts across lymphoma, ovarian cancer and head and neck cancer could support multiple potential product launches beginning in 2027, as the company seeks to increase growth from medicines it owns or…
Genmab scores a ‘hat trick’ with positive data for its experimental cancer drug, petosemtamab, Jefferies says.
Genmab A/S (NASDAQ:GMAB) stock surged to a 52-week high after the company delivered positive topline findings from its global Phase 3 LiGeR-HN1 clinical trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting EGFR and LGR5.
Genmab’s Petosemtamab, when combined with Merck’s blockbuster cancer therapy Keytruda, reduced the risk of death by 50% compared with Keytruda alone.
Investing.com -- Genmab A/S (NASDAQ:GMAB) shares rose 16% Wednesday after the company announced its experimental drug petosemtamab reduced the risk of death by 50% in a head and neck cancer trial.
Investing.com -- J.P. Morgan upgraded biotechnology company Genmab A/S to "overweight" from "neutral" and raised its price target to DKr3,500 from DKr2,050, saying it expects positive November results from a late-stage trial of Genmab’s head and neck cancer…
Genmab reported updated Phase 2 data for petosemtamab in head and neck and colorectal cancer, along with a new clinical trial collaboration with Incyte on KRAS G12D-mutated metastatic colorectal cancer.